BenevolentAI Investor Conference Presentation Deck

Our pipeline products are highly differentiated Target Market Potential Key Differentiators Asset BEN-8744: Ulcerative Colitis (UC) BEN-28010: Glioblastoma Multiforme (GBM) BEN-34712: Amyotrophic Lateral Sclerosis (ALS) Parkinson's Disease Fibrosis MOA PDE10 inhibitor CHKI inhibitor RARaß agonist Novel Target Novel Target Moderate-to-severe Ulcerative Colitis Naive and recurrent GBM regardless of MGMT methylation status Sporadic and familial forms of ALS Parkinson's and related synucleinopathies Fibrotic indications including NASH • Novel therapeutic approach: potential first-in-class peripherally restricted small molecule for the treatment of UC Discovery & Development Pipeline • Potential for meaningful differentiation from existing immunosuppressive standard-of care treatments, through disease modifying efficacy • Potential first-in-class CNS penetrant drug for GBM and metastatic brain tumours • Potential efficacy in patients resistant to chemotherapeutic SoC agents Strong rationale for combination therapy approaches in non-CNS cancers ● • Potential best-in-class CNS penetrant subtype-selective approach to drive efficacy and minimise side effect profile Neuroprotective mechanism of action, with positive effects in SOD1 mouse model ● • Potential first-in-class CNS penetrant drug with neuroprotective activity • Novel target focused on the underlying mechanisms of fibrotic diseases - broad spectrum therapeutic potential BenevolentAl Proprietary Benevolent 7

View entire presentation